Sigma-1 Receptor Agonists in Neurodegenerative Disease

📖 Wiki Page

therapeutic2400 wordssynced 2026-04-02

Sigma-1 Receptor Agonist Therapy

...

Sigma-1 Receptor Agonist Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Sigma-1 Receptor Agonists in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M1.1 Lead optimization</td>
<td>Optimize S1R agonists (pridopidine analogs) for [BBB](/entities/blood-brain-barrier) penetration and selectivity</td>
</tr>
<tr>
<td class="label">M1.2 iPSC neuronal assays</td>
<td>Test lead compounds on patient-derived neurons (AD, PD, ALS) for neuroprotection</td>
</tr>
<tr>
<td class="label">M1.3 In vivo efficacy</td>
<td>[APP](/entities/app-protein)/PS1 and alpha-synuclein mouse models with cognitive/motor endpoints</td>
</tr>
<tr>
<td class="label">M1.4 GLP toxicology</td>
<td>28-day rat toxicology for lead S1R agonist</td>
</tr>
<tr>
<td class="label">M1.5 IND package</td>
<td>CMC, pharmacology, toxicology compilation</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M2.1 Phase 1a SAD/MAD</td>
<td>Single/multiple ascending dose in healthy volunteers</td>
</tr>
<tr>
<td class="label">M2.2 Phase 1b</td>
<td>Biomarker-stratified patients with cognitive/motor endpoints</td>
</tr>
<tr>
<td class="label">M2.3 Biomarker validation</td>
<td>ER stress markers (BIP, CHOP), mitochondrial function assays</td>
</tr>
<tr>
<td class="label">Milestone</td>
<td>Activities</td>
</tr>
<tr>
<td class="label">M3.1 Phase 2 RCT</td>
<td>Randomized controlled in 100 early AD/PD patients</td>
</tr>
<tr>
<td class="label">M3.2 Biomarker stratification</td>
<td>Genetic analysis ([APOE](/genes/apoe), LRRK2, SOD1), ER stress markers</td>
</tr>
<tr>
<td class="label">M3.3 Long-term extension</td>
<td>12-month open-label safety</td>
</tr>
<tr>
<td class="label">Institution</td>
<td>Investigator</td>
</tr>
<tr>
<td class="label">University of California, San Francisco</td>
<td>Dr. Stephen Stahl</td>
</tr>
<tr>
<td class="label">University of Michigan</td>
<td>Dr. Henry Paulson</td>
</tr>
<tr>
<td class="label">University of Southern California</td>
<td>Dr. Terrence Town</td>
</tr>
<tr>
<td class="label">Karolinska Institute</td>
<td>Dr. Lars B. Sharpe</td>
</tr>
<tr>
<td class="label">University of Florida</td>
<td>Dr. Paramita Chakrabarty</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Program</td>
</tr>
<tr>
<td class="label">Prilenia Therapeutics</td>
<td>Pridopidine (ACPD)</td>
</tr>
<tr>
<td class="label">AstraZeneca</td>
<td>S1R modulators</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Neurodegeneration pipeline</td>
</tr>
<tr>
<td class="label">Eli Lilly</td>
<td>S1R for AD</td>
</tr>
<tr>
<td class="label">NeuroTherapia</td>
<td>S1R agonists</td>
</tr>
<tr>
<td class="label">Risk</td>
<td>Likelihood</td>
</tr>
<tr>
<td class="label">Limited brain penetration</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Off-target effects</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Clinical efficacy unclear</td>
<td>Medium</td>
</tr>
<tr>
<td class="label">Competition from pridopidine</td>
<td>High</td>
</tr>
</table>

Introduction

The Sigma-1 Receptor (S1R) is a unique transmembrane protein primarily localized to the endoplasmic reticulum (ER) that functions as a molecular chaperone and calcium sensor. S1R has emerged as a promising therapeutic target for neurodegenerative diseases due to its critical roles in ER stress response, mitochondrial function, calcium homeostasis, and neuroprotection. Sigma-1 Receptor agonists represent a novel approach to treating Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS) by targeting these fundamental cellular pathways that become dysregulated during neurodegeneration. [@maurice2009]

The Sigma-1 Receptor is distinct from other known receptor families and exhibits high affinity for various pharmacological ligands including neuroactive steroids, certain antidepressants, and selective experimental compounds. This receptor's pleiotropic effects on cellular homeostasis make it an attractive target for addressing the complex pathophysiology of neurodegenerative disorders. [@cai2020]

Molecular Biology of Sigma-1 Receptor

Structure and Localization

The Sigma-1 Receptor is a 223-amino acid protein that resides predominantly in the ER membrane, particularly at the mitochondria-associated membranes (MAMs) where the ER makes close contact with mitochondria. This strategic positioning allows S1R to serve as a key regulator of calcium signaling between these two organelles and coordinate cellular responses to stress. [@francardo2014]

The receptor contains a single transmembrane domain and operates as a ligand-operated chaperone. Unlike classical G-protein coupled receptors, S1R modulates ion channel activity and signaling pathways through protein-protein interactions rather than classical second messenger systems. [@mancuso2021]

Sigma-1 Receptor Signaling Pathways

Mermaid diagram (expand to render)

Mechanism of Action

Endoplasmic Reticulum Chaperone Function

Upon ligand binding, Sigma-1 Receptor undergoes conformational changes that enhance its chaperone activity within the ER. This enhanced chaperone function helps maintain protein folding homeostasis and attenuates the [unfolded protein response](/entities/unfolded-protein-response) (UPR), which is chronically activated in many neurodegenerative diseases. The S1R can directly interact with various client proteins including inositol 1,4,5-trisphosphate receptors (IP3Rs) to modulate calcium release and restore ER function. [@ryskamp2019]

For more information on ER stress mechanisms, see [ER Stress and Unfolded Protein Response Pathway](/mechanisms/er-stress-unfolded-protein-response). [@wollmer2011]

Calcium Homeostasis Regulation

S1R activation promotes calcium signaling across the mitochondria-associated membranes (MAMs), facilitating proper calcium exchange between the ER and mitochondria. This calcium transfer is essential for mitochondrial ATP production and cellular bioenergetics. In neurodegenerative diseases, calcium dysregulation contributes to mitochondrial dysfunction, excitotoxicity, and neuronal death. [@tagashira2014]

See [Calcium Dysregulation in Neurodegeneration](/calcium-dysregulation-in-neurodegeneration) for more details. [@tsai2015]

Mitochondrial Protection

Sigma-1 Receptor agonists protect mitochondrial function through multiple mechanisms: [@miki2015]

Enhancement of mitochondrial calcium uptake and ATP production
Reduction of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) generation
Preservation of mitochondrial membrane potential
Promotion of mitochondrial biogenesis
Protection against mitochondrial permeability transition

For comprehensive information on mitochondrial dysfunction in neurodegeneration, see [Mitochondrial Dysfunction in Neurodegeneration](/mitochondrial-dysfunction-in-neurodegeneration). [@ono2014]

Anti-apoptotic Effects

S1R activation triggers pro-survival signaling cascades including: [@hayashi2007]

Activation of Akt/PKB signaling
Enhancement of brain-derived neurotrophic factor (BDNF) signaling
Inhibition of caspase activation
Modulation of Bcl-2 family proteins
Reduction of endoplasmic reticulum stress-induced [apoptosis](/mechanisms/apoptosis)

Preclinical Evidence

Alzheimer's Disease Models

In Alzheimer's Disease models, Sigma-1 Receptor agonists have demonstrated multiple beneficial effects: [@matsumoto2015]

[Amyloid-beta](/proteins/amyloid-beta) protection: S1R activation reduces amyloid-beta-induced neurotoxicity and improves synaptic function

[Tau](/proteins/tau) pathology modulation: Evidence suggests S1R agonists may reduce [tau](/proteins/tau) phosphorylation and aggregation

Cognitive improvement: Animal studies show enhanced memory and learning in AD models

Neuroinflammation reduction: S1R agonists attenuate microglial activation and inflammatory responses

Parkinson's Disease Models

In PD models, Sigma-1 Receptor agonists show particular promise: [@saft2020]

Dopaminergic neuron protection: S1R activation protects dopaminergic [neurons](/entities/neurons) from [alpha-synuclein](/proteins/alpha-synuclein) toxicity and oxidative stress

Mitochondrial preservation: Enhanced mitochondrial function in substantia nigra pars compacta

Motor function improvement: Behavioral assessments show improved motor performance

Neuroinflammation modulation: Reduced microglial activation in PD models

Amyotrophic Lateral Sclerosis Models

Preclinical evidence in ALS models demonstrates: [@uchida2020]

Motor neuron protection: S1R agonists protect against excitotoxicity and oxidative damage

Slowed disease progression: Extended survival in SOD1 mutant mouse models

Muscle function preservation: Improved neuromuscular junction integrity

Glial cell modulation: Effects on astrocyte and [microglia](/cell-types/microglia) function

Clinical Trial Status

Pridopidine

Pridopidine (formerly known as ACR16) is the most advanced Sigma-1 Receptor agonist in clinical development: [@guzman2022]

Parkinson's Disease: Completed Phase II trials (HART-PD) showing good safety and potential efficacy for motor symptoms
Huntington's Disease: Extensive clinical trial history (HART, MermaiHD, PRIDE-HD) establishing safety profile
ALS: Phase II trial (LIONESS) completed, showing good safety in patients
Mechanism: Pridopidine has high affinity for S1R with additional dopamine D2 receptor modulation

SA4503 (Cutamesine)

SA4503 is a selective Sigma-1 Receptor agonist that has been investigated: [@peviani2022]

Depression: Phase II trials completed showing antidepressant effects
Neuroprotection: Preclinical data supports potential for AD and PD
Cognitive enhancement: Animal studies demonstrate cognitive improvements
Clinical status: Further clinical development for neurodegeneration is warranted

Other Clinical Candidates

Several other S1R agonists are in various stages of development: [@kourrich2012]

[Donepezil](/therapeutics/donepezil) derivatives: Some acetylcholinesterase inhibitors also possess S1R agonist activity
Neuroactive steroids: endogenous S1R ligands in clinical investigation
Fluvoxamine: SSRI with S1R agonist properties being investigated for neuroprotection

Safety Profile

Sigma-1 Receptor agonists have generally demonstrated favorable safety profiles in clinical trials: [@bridges2012]

Common Adverse Effects

Mild central nervous system effects (dizziness, headache)
Gastrointestinal symptoms (nausea, constipation)
Sleep disturbances

Serious Considerations

Potential for psychiatric effects at high doses
Drug-drug interactions with other CNS-active medications
Long-term safety data still being collected

Advantages

No significant hepatotoxicity observed
Low risk of addiction or dependence
Wide therapeutic window in preclinical models

Cross-Linking to Disease Mechanisms

Sigma-1 Receptor agonists intersect with multiple neurodegenerative disease pathways: [@wang2021]

Alzheimer's Disease

[Alzheimer's Disease](/diseases/alzheimers-disease) - Main disease page
[Calcium Dysregulation in Alzheimer's Disease](/mechanisms/calcium-dysregulation-alzheimers) - Calcium pathway interactions
[Mitochondrial Dysfunction in Alzheimer's Disease](/mechanisms/mitochondrial-dysfunction-ad) - Mitochondrial protection
[ER Stress in Neurodegeneration](/mechanisms/er-stress-pathway) - ER stress modulation

Parkinson's Disease

[Parkinson's Disease](/diseases/parkinsons-disease) - Main disease page
[Mitochondrial Dysfunction in Parkinson's Disease](/mechanisms/mitochondrial-dysfunction-parkinson) - Mitochondrial pathways
[Alpha-Synuclein Immunotherapy](/therapeutics/alpha-synuclein-immunotherapy) - Synuclein targeting

Amyotrophic Lateral Sclerosis

[Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) - Main disease page
[ALS-FTD Spectrum](/diseases/als-ftd-spectrum) - Related conditions

General Neurodegeneration Mechanisms

[ER-Mitochondria Contact Sites (MAMs)](/mechanisms/er-mitochondria-contact-sites) - S1R location and function
[Neuroinflammation Cross-Disease](/mechanisms/neuroinflammation-cross-disease) - Inflammatory modulation
[Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control) - Mitochondrial protection

Therapeutic Implications and Future Directions

Sigma-1 Receptor agonists represent a promising disease-modifying approach for neurodegenerative disorders due to their pleiotropic neuroprotective effects. The ability to simultaneously target ER stress, mitochondrial dysfunction, and calcium dysregulation addresses multiple hallmarks of neurodegeneration rather than single pathways. [@nguyen2023]

Research Gaps and Opportunities

Biomarker development: Need for S1R engagement biomarkers to guide dosing

Combination therapy: Potential synergy with other disease-modifying approaches

Genetic stratification: Understanding how S1R genetic variants affect response

Delivery optimization: Improving brain penetration and target engagement

Patient selection: Identifying patients most likely to benefit from S1R-targeted therapy

Clinical Development Priorities

Phase III trials for pridopidine in PD and ALS
Development of more selective S1R agonists
Long-term safety and disease-modification studies
Biomarker-driven patient selection approaches

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Implementation Roadmap with Cost Estimates

Phase 1: Discovery & Preclinical (Months 1-15)

Phase 1 Total: ~$1,350,000

Phase 2: Phase 1 Clinical (Months 16-28)

Phase 2 Total: ~$3,220,000

Phase 3: Phase 2 Clinical (Months 29-48)

Phase 3 Total: ~$6,000,000

Total Program Cost: ~$10.5-11 million

Key Academic Centers & Investigators

Companies with Relevant Programs

Risk Assessment

Actionable Next Steps

Immediate (3 months)

Commission medicinal chemistry: optimize pridopidine analogs for enhanced S1R selectivity and brain penetration
Establish CLIA-validated ER stress biomarker panel (BIP, CHOP, ATF4) for clinical use
iPSC bank: collect 15+ patient-derived neuron lines (APOE4, LRRK2 G2019S, [C9orf72](/entities/c9orf72), sporadic)

Near-term (6 months)

GLP toxicology: 28-day rat study with lead S1R agonist
Submit IND-enabling package to FDA
Engage KOLs at American Academy of Neurology for trial design input

Platform (12+ months)

Phase 1/2 trial design: adaptive platform for multiple neurodegenerative indications
Partner with patient advocacy groups (Alzheimer's Association, Michael J. Fox Foundation, ALS Association)
Develop companion diagnostic: ER stress biomarker threshold for patient enrichment

Key Research Gaps

Validate S1R agonist mechanism in human neurons vs rodent models
Assess long-term effects of sustained S1R activation
Evaluate synergy with [GLP-1 receptor](/entities/glp1-receptor) agonists and NAD+ boosters

Clinical Development Path

Phase 1: First-in-human safety with ER stress biomarker readouts

Phase 2a: Biomarker-enriched study in early AD/PD (n=80) with cognitive endpoints

Phase 2b: Expand to ALS/FTD with other mechanisms

Academic Partners

UCSF (Dr. S. Stahl) — S1R pharmacology expertise
USC (Dr. T. Town) — AD model expertise
University of Michigan (Dr. H. Paulson) — neurodegeneration therapeutics

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Unknown, Maurice, T. & Su, T.P. The pharmacology of sigma-1 receptors (2009) (2009)](https://doi.org/10.1016/j.pharmthera.2009.01.001)

[Cai, J. et al., Sigma-1 receptor protects against endoplasmic reticulum stress in Alzheimer's disease (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32895526/)

[Francardo, V. et al., Pridopidine induces neuroprotection in models of Parkinson's disease (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25322956/)

[Mancuso, R. et al., Sigma-1 receptor in Amyotrophic Lateral Sclerosis (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34044015/)

[Ryskamp, D. et al., The Sigma-1 Receptor as a Ca2+ sensor and modulator of mitochondrial function (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30789836/)

[Wollmer, M.A. et al., Pridopidine for the treatment of Huntington's disease (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21815647/)

[Tagashira, H. et al., SA4503, a selective sigma-1 receptor agonist, as a potential therapeutic agent for Alzheimer's disease (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25130282/)

[Tsai, S.Y. et al., Sigma-1 receptors regulate hippocampal neuronal excitability (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25747177/)

[Miki, Y. et al., Sigma-1 receptor agonists improve motor function in animal models of Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26215626/)

[Ono, M. et al., Neuroprotective effects of sigma-1 receptor ligands in neurodegenerative diseases (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24798552/)

[Unknown, Hayashi, T. & Su, T.P. Sigma-1 receptors at the endoplasmic reticulum-mitochondria interface (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17387608/)

[Matsumoto, R.R. et al., Sigma receptors: Potential targets for neuroprotection (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25868374/)

[Saft, C. et al., Pridopidine in Huntington's disease: Current status (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32093467/)

[Uchida, N. et al., Sigma-1 receptor agonists for the treatment of cognitive disorders (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32247219/)

[Guzman, R.E. et al., Sigma-1 Receptor agonists and mitochondrial dysfunction in neurodegeneration (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35649628/)

[Peviani, M. et al., Neuroprotective effects of Sigma-1 receptor stimulation in ALS models (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36178691/)

[Kourrich, S. et al., The Sigma-1 Receptor: A molecular chaperone for cellular homeostasis (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22903883/)

[Bridges, T.M. et al., The Sigma-1 Receptor and its role in neurological disorders (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22506747/)

[Wang, J. et al., Sigma-1 receptor activation ameliorates mitochondrial dysfunction in Alzheimer's disease (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34082561/)

[Nguyen, L. et al., Targeting Sigma-1 Receptor for Neurodegenerative Disease Treatment (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37054218/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — 0.59 · Target: APOE
[APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — 0.61 · Target: APOE
[Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — 0.56 · Target: APOE
[Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — 0.55 · Target: APOE, LRP1, LDLR
[Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — 0.51 · Target: APOE
[Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — 0.46 · Target: APOE

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

📖 View canonical wiki page →

Sigma-1 Receptor Agonists in Neurodegenerative Disease

Sigma-1 Receptor Agonist Therapy

Sigma-1 Receptor Agonist Therapy

Introduction

Molecular Biology of Sigma-1 Receptor

Structure and Localization

Sigma-1 Receptor Signaling Pathways

Mechanism of Action

Endoplasmic Reticulum Chaperone Function

Calcium Homeostasis Regulation

Mitochondrial Protection

Anti-apoptotic Effects

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Amyotrophic Lateral Sclerosis Models

Clinical Trial Status

Pridopidine

SA4503 (Cutamesine)

Other Clinical Candidates

Safety Profile

Common Adverse Effects

Serious Considerations

Advantages

Cross-Linking to Disease Mechanisms

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

General Neurodegeneration Mechanisms

Therapeutic Implications and Future Directions

Research Gaps and Opportunities

Clinical Development Priorities

See Also

External Links

Implementation Roadmap with Cost Estimates

Phase 1: Discovery & Preclinical (Months 1-15)

Phase 2: Phase 1 Clinical (Months 16-28)

Phase 3: Phase 2 Clinical (Months 29-48)

Total Program Cost: ~$10.5-11 million

Key Academic Centers & Investigators

Companies with Relevant Programs

Risk Assessment

Actionable Next Steps

Immediate (3 months)

Near-term (6 months)

Platform (12+ months)

Key Research Gaps

Clinical Development Path

Academic Partners

Allen Brain Atlas Resources

References

Related Hypotheses